PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 41):
The composition of  claim 39  wherein the composition comprises a drug combination comprising:\n (i) bisantrene; and \n (ii) an additional therapeutic agent selected from the group consisting of:\n (a) fraudulent nucleosides; \n (b) fraudulent nucleotides; \n (c) thymidylate synthetase inhibitors; \n (d) signal transduction inhibitors; \n (e) cisplatin or platinum analogs; \n (f) alkylating agents; \n (g) anti-tubulin agents; \n (h) antimetabolites; \n (i) berberine; \n (j) apigenin; \n (k) colchicine or an analog thereof; \n (l) genistein; \n (m) etoposide; \n (n) cytarabine; \n (o) camptothecins; \n (p)  vinca  alkaloids; \n (q) topoisomerase inhibitors; \n (r) 5-fluorouracil; \n (s) curcumin; \n (t) rosmarinic acid; \n (u) mitoguazone; \n (v) meisoindigo; \n (w) imatinib; \n (x) dasatinib; \n (y) nilotinib; \n (z) epigenetic modulators; \n (aa) transcription factor inhibitors; \n (ab) taxol; \n (ac) homoharringtonine; \n (ad) pyridoxal; \n (ae) spirogermanium; \n (af) caffeine; \n (ag) nicotinamide; \n (ah) methylglyoxalbisguanylhydrazone; \n (ai) PARP inhibitors; \n (aj) EGFR inhibitors; \n (ak) Bruton's tyrosine kinase (BTK) inhibitors; \n (al) bis-[thio-hydrazide] amides; \n (am) succinimide or maleimide derivatives as inhibitors of topoisomerase II; \n (an) histone deacetylase (HDAC) inhibitors; \n (ao) immunostimulants; \n (ap) telomerase inhibitors; \n (aq) inhibitors of the expression or activity of Her2; \n (at) inhibitors of the expression of activity of estrogen receptors; \n (as) inhibitors of the expression or activity of an antigen associated with a specific tumor targets; \n (at) G-quadruplex ligands; \n (au) polycyclic lysophosphatidic receptor antagonists; \n (av) anti-CTGF agents; \n (aw) myeloid differentiation inducing agents; \n (ax) covalent diabodies binding to a tumor-associated antigen; \n (ay) bispecific antibodies that have a cell-penetrating determinant and an intracellular target-binding determinant; \n (az) multidomain molecules that comprise a cell binding ligand that binds to cells in the tumor stroma such as endothelial cells, fibroblasts, or immune cells and an oligonucleotide that inhibits the nonsense-mediated decay pathway; \n (ba) tumor-specific antibodies binding to a portion of the CD44 protein or a binding protein derived from the light-chain or heavy-chain complementary-determining regions of such antibodies; \n (bb) inhibitors of CXCR4; \n (bc) pyruvate dehydrogenase kinase (PDK1) inhibitors; \n (bd) epherin receptor targeting agents; \n (be) binding proteins for Axl; \n (bf) Wnt pathway inhibitors together with MAPK pathway inhibitors; \n (bg) TEC family kinase inhibitors; \n (bh) substituted macrocyclic compounds with proteasome activity; \n (bi) peptide-based PACE4 inhibitors; \n (bj) azaindole derivatives as JAK3 inhibitors; \n (bk) inhibitors of Myc; \n (bl) inhibitors of furin and other pro-protein convertases; \n (bm) GPBP-1 inhibitors, optionally together with a p21 inhibitor; \n (bn) PGE 2  inhibitors; and \n (bo) use with activatable antibodies targeting tumor-specific markers.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7751803528845034
- 35 USC 102 Novelty (BERT): 0.5314597139065973
- Combined Prediction Score: 0.7508082889867127
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 250.6449092029667

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test